TELA Bio (TELA)
(Delayed Data from NSDQ)
$2.54 USD
+0.05 (2.01%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $2.56 +0.02 (0.79%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.54 USD
+0.05 (2.01%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $2.56 +0.02 (0.79%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Zacks News
TELA Bio, Inc. (TELA) Stock Jumps 6.6%: Will It Continue to Soar?
by Zacks Equity Research
TELA Bio, Inc. (TELA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -50% and 4.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of 1.63% and 0.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Cytokinetics (CYTK): Can Its 11.5% Jump Turn into More Strength?
by Zacks Equity Research
Cytokinetics (CYTK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -9.26% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 10.77% and 26.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -5.88% and 30.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OYSTER PT PHARM (OYST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -15.83% and 1,206.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -9.62% and 4.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will TELA Bio, Inc. (TELA) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
TELA Bio, Inc. (TELA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TELA Bio, Inc. (TELA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -16.33% and 18.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
TELA Bio, Inc. (TELA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for June 18th
by Zacks Equity Research
OEG, EAF, RARE, EGRX, and TELA have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2021
TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -27.27% and 4.02%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
TELA Bio, Inc. (TELA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -5.88% and 1.20%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?